TX-MAVENIR
11.2.2020 14:02:08 CET | Business Wire | Press release
Mavenir, the industry's only end-to-end cloud-native 4G/5G network software provider for CSPs, has announced collaboration and joint go-to-market with MUGLER, a leading and well-established neutral system integrator for telco networks in Germany, to deliver Mavenir’s end-to-end 5G solutions including 5G vRAN, 5G Core & Digital Enablement Platform to the German Enterprise & Industry Market, enabled by the German Government’s Private Networks initiative and the allocation of spectrum for private enterprise and industry use.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200211005394/en/
Mavenir will offer its full portfolio of 4G and 5G solutions for the German Private Networks market to address the needs of Enterprises, Industries and Service Providers. Mugler will act as go to market partner for Mavenir as well as a value-added reseller including systems integration and local operation and support. In addition, Mugler has secured a private networks license from BNetzA (the German frequency regulator) and will deploy an end-to-end 5G system on its own campus at Oberlungwitz (Saxony, Germany). This network will be used for advanced enterprise use cases such as AGVs for logistics, AR/VR, IoT, Video, Broadcast and Secure Communications for Mugler’s enterprise needs, as well as a showcase and testbed for end customers.
Jointly, the companies will address the growing business opportunity for private networks for the Industry, Media, Health, Public Authorities and Service Provider segments and customers.
A Comprehensive Private Networks Solution for Enterprises and Industries
The German Government’s private networks initiative has allocated spectrum in the 3.7-3.8 GHz band for enterprises and industries to build their own mobile networks in environments such as campuses, venues, offices, factories and ports etc.
Mavenir’s OpenRAN vRAN encompasses 4G and 5G radio access, and the disaggregated RAN approach extends virtualization to the edge of the network and provides strategic differentiation by enabling multisource Remote Radio Units (RRUs) to interwork with the virtualized, containerized, Cloud Base Band software over ethernet Fronthaul (FH), using the O-RAN open interface overcoming the traditional constraints of the proprietary walled garden specifications used by the other traditional equipment vendors.
Mavenir’s 5G Core solution , based on cloud-native principles, can be retrofitted on EPCs and encompasses all the major 5G core elements, and these functions are implemented as micro-services in containers. The Mavenir 5G Core also combines 4G EPC functionality and offers a ‘Converged Mobile Core’ solution that supports both 4G and 5G subscribers. In addition, the Mavenir 5G Core supports all Standalone (SA) and Non-Standalone (NSA) options.
Mavenir’s Digital Enablement platform allows Private Network operators to create a seamless way of abstracting out the complexity of the underlying network, and create a digital app store for enterprise and industry applications – thereby empowering an ecosystem of developers, service providers, technology companies, enterprises and industries to create applications to power digitalization with 5G.
This end-to-end 5G system, based on cloud-first and open architecture principles, is highly suited to address both mass scale private enterprise use cases as well as bespoke high-end use cases for advanced industries. The solution can be delivered as on-prem “network-in-a-box”, cloud-based “Network-as-a-Service” or Hybrid models.
With Mugler’s advanced services those networks can be deployed as turn-key solutions anywhere in Germany and beyond. Furthermore, Mugler’s Telco mplete® - Process covers the whole lifecycle of telco networks and infrastructure with all managed services, including end to end network design and planning, systems integration, deployment, support, maintenance, repair and field service 365/24/7.
Quotes
“As 5G use cases are emerging, together with Mugler, we are bringing our 4G/5G virtualized portfolio of solutions to the German market for quick and easy deployments,” said Aniruddho Basu, Mavenir’s SVP/GM of Emerging Business. “Mavenir’s OpenRAN vRAN and Converged Mobile Core solutions provide a cost-efficient approach to addressing the rising need for private networks for enterprises, industries and service providers.”
“Private networks will revolutionize a lot of industries. They will have an enormous leverage for digitization,” said Fabian Berger, Mugler’s Director Local Networks. “To deploy and operate those networks flexibly and cost effectively, OpenRAN and virtualized networks are up-and-coming. We see Mavenir as a strong partner to be able to quickly develop and deploy customized private networks for different industries and customers.”
About Mavenir
Mavenir is the industry's only end-to-end, cloud-native Network Software Provider focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs) by offering a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC, and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 140 countries, which serve over 50% of the world’s subscribers.
We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve webscale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. Learn more at www.mavenir.com
About Mugler
Mugler is a medium-sized company based and mainly active in Germany. Since the foundation of our company in 1990, we have become a well-established and leading service provider and neutral system integrator for telecommunication networks and infrastructure in Germany. Today 320 employees implement our slogan “from idea to network” with our full-service Telco mplete®-Process, covering the complete lifecycle of all kinds of telecommunication infrastructure including network design and planning, systems integration, deployment, maintenance, operation and support.
With this and our long lasting know-how we are able to provide and maintain sustainable networks to all kinds of customers, from the large German CSPs (mobile and fixed) to public authorities, as well as large and smaller companies.
Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.
Copyright © 2020 Mavenir Systems, Inc. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005394/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
